Q-omics provides the consensus-scored RPSAP20 profile across patient tissues and cancer cell-line models. RPSAP20 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPSAP20 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPSAP20 RNA expression shows 8,960 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, KIRC, and CCRCC as cancer lineages where RPSAP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP20 survival associations across molecular data types. RPSAP20 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP20 RNA expression–survival associations across cancer types. High RPSAP20 expression shows unfavorable associations in ACC, BRCA, PRAD, CESC, KIRP and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify ACC as the clearest survival context for RPSAP20 RNA expression.
This table summarizes RPSAP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP20 shows lower tumor expression in BRCA, PAAD, KIRP and THCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher RPSAP20 RNA expression in tumor versus normal tissue (log2 FC = +0.109, t-test p < 0.001).
This table shows molecular features associated with RPSAP20 in patient tissues and cancer cell lines. In patient samples, RPSAP20 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
